List of Sovaldi drug patents

Sovaldi is owned by Gilead Sciences Inc.

Sovaldi contains Sofosbuvir.

Sovaldi has a total of 18 drug patents out of which 0 drug patents have expired.

Sovaldi was authorised for market use on 06 December, 2013.

Sovaldi is available in tablet;oral dosage forms.

Sovaldi can be used as for the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin, for the treatment of hepatitis c.

The generics of Sovaldi are possible to be released after 11 June, 2031.

SOVALDI's oppositions filed in EPO
SOVALDI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US9549941 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9549941

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Aug 28, 2026
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using SOFOSBUVIR ingredient

Market Authorisation Date: 06 December, 2013

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin

Dosage: TABLET;ORAL

How can I launch a generic of SOVALDI before it's patent expiration?
More Information on Dosage

SOVALDI family patents

56

United States

21

European Union

20

Japan

17

China

14

Hong Kong

12

Singapore

12

Spain

12

Canada

11

Korea, Republic of

10

Brazil

9

Portugal

9

New Zealand

9

Taiwan, Province of China

9

Israel

9

Chile

8

Argentina

8

Mexico

7

EA

7

South Africa

7

Slovenia

7

Poland

7

Australia

6

Colombia

5

Uruguay

5

Croatia

5

Cyprus

5

Hungary

5

Denmark

4

Russia

4

Costa Rica

4

Philippines

4

Peru

4

Lithuania

4

Ecuador

3

Germany

3

Malaysia

3

ME

3

Ukraine

3

RS

2

Moldova, Republic of

2

San Marino

2

Morocco

1

Turkey

1

AP

1

Norway

1

Luxembourg

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic